SALT LAKE CITY--(EON: Enhanced Online News)--Recursion Pharmaceuticals announced that it has won two Fierce Innovation awards from the biotech and pharmaceutical industries today for its innovative platform. The awards, ‘Best Biotech Innovation’ and ‘Best In Show - New Product or Service,’ recognize Recursion’s disruptive combination of experimental biology and artificial intelligence applied to drug discovery.
“Traditional drug discovery can take more than a decade and billions of dollars per approved compound”
“We are pleased to be recognized as industry-leading innovators by our distinguished peers,” said Chris Gibson, co-founder and CEO of Recursion. “Our platform represents a different approach to drug discovery - a true merging of biology and technology.”
“Traditional drug discovery can take more than a decade and billions of dollars per approved compound,” Gibson continued. “Recursion’s platform can radically increase the scale at which drugs are discovered, saving years of development time and the associated costs.”
The Fierce Innovation Awards: Life Sciences Edition is an awards program from the publisher of FierceBiotech and FiercePharma. Recursion’s computationally intelligent platform was recognized for its ability to span the life science industry, from drug screening to target identification to compound intelligence.
“Because we model diseases and conditions in human cells, our platform can be deployed across nearly any aspect of human cellular biology,” said Gibson. “Drug discovery is the first and most advanced of Recursion’s real-world applications.”
In less than a year, Recursion has screened hundreds of disease models and identified more than twelve compounds across seven disease states that show sufficient potential to advance to preclinical development.
Fierce Innovation award applications are reviewed by an exclusive panel of executives from Medidata, PwC, Verily, Otsuka Pharmaceuticals, Amgen and more. Profiles of the judges can be found at www.fierceinnovationawards.com/life-science/2016#our_judges.
Judges based their decision on effectiveness, technical innovation, competitive advantage, financial impact and true innovation. Recursion’s platform was selected from among five finalists in Biotech Innovation by championing innovation in the face of great competition, with forward thinking and the greatest potential to have the biggest impact on the industry. Recursion was a finalist alongside such outstanding innovators as Bicycle Therapeutics, Humacyte, Covance, LexisNexis, The Michael J Fox Foundation, and Bayer AG + Facebook.
Recursion Pharmaceuticals is a Salt Lake City-based life science company. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Learn more at www.recursionpharma.com, or connect on Twitter (@RecursionPharma), Facebook (www.facebook.com/RecursionPharma/), and LinkedIn (https://www.linkedin.com/company/recursion-pharmaceuticals).
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, finance, and retail industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries.